Related Experiment Video
Updated: Jul 25, 2026
10:55
Fluorescence-quenching of a Liposomal-encapsulated Near-infrared Fluorophore as a Tool for In Vivo Optical Imaging
Published on: January 5, 2015
New Fluoroquinolones: Real and Potential Roles
Ball1
16, Gilchrist Row, St. Andrews, Fife KY16 8XU, Scotland.
Current Infectious Disease Reports
|November 30, 2000
Summary
Third-generation fluoroquinolones offer improved efficacy against Gram-positive and anaerobic bacteria, addressing limitations of older drugs. These new agents show promise in treating respiratory and surgical infections, though differing side effect profiles require consideration.
Area of Science:
- Pharmacology
- Infectious Diseases
- Microbiology
Background:
- Second-generation fluoroquinolones have a decade-long history of safe and effective clinical use.
- Limitations exist regarding activity against Gram-positive and anaerobic organisms, restricting their use in certain infections.
- These limitations necessitate the development of new antimicrobial agents.
Purpose of the Study:
- To evaluate the efficacy and safety of third-generation fluoroquinolones.
- To compare the activity of new fluoroquinolones against Gram-positive and anaerobic bacteria, including key pathogens like Streptococcus pneumoniae and Bacteroides fragilis.
- To assess the role of these agents in treating respiratory, intra-abdominal, pelvic, surgical, and gynecologic infections.
Main Methods:
- Clinical trials evaluating third-generation fluoroquinolones.
- Microbiological studies assessing in vitro activity against relevant pathogens.
- Comparative analysis of efficacy and adverse reaction profiles.
Main Results:
- Third-generation fluoroquinolones demonstrate significantly enhanced activity against Gram-positive and anaerobic bacteria.
- High efficacy rates were observed in pneumonia, bronchitis, and surgical/gynecologic infections.
- While clinical outcomes are often similar, distinct adverse reaction profiles exist among the new agents.
Conclusions:
- Third-generation fluoroquinolones represent a significant advancement, overcoming the limitations of earlier generations.
- These agents offer effective treatment options for a broader range of infections, particularly those involving Gram-positive and anaerobic pathogens.
- Therapeutic selection may be influenced by the differing adverse event profiles of these novel fluoroquinolone drugs.
Related Concept Videos
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
01:15Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions
PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure (CHF).
01:28Gene Regulation in Microbial Communities: Quorum Sensing
Quorum sensing is a mechanism of bacterial communication that enables coordinated gene expression in response to changes in population density. This facilitates collective behaviors that enhance survival, resource acquisition, and ecological adaptation. This process relies on small signaling molecules called autoinducers that accumulate as bacterial populations grow. When a critical threshold concentration of autoinducers is reached, bacterial cells collectively modify gene expression,...
01:25Mechanism of Antibiotic Resistance in MRSA
Antibiotic resistance in bacteria arises when microorganisms evolve the ability to withstand drugs designed to kill them or inhibit their growth, rendering once-effective treatments useless. This phenomenon, driven by genetic change and selection under antibiotic exposure, poses a profound threat to modern medicine. Mechanisms include drug-inactivating enzymes (e.g., β-lactamases), efflux pumps that eject antibiotics, mutations altering antibiotic targets, decreased drug uptake, and acquisition...
01:28Inhibitors of Bacterial DNA Synthesis
Bacterial pathogens depend on precise and efficient DNA replication to sustain infection. Two type II topoisomerases—DNA gyrase and topoisomerase IV—are critical to this process, as they resolve DNA supercoiling and unlink chromosomes during replication. Fluoroquinolones, synthetic derivatives of quinolones, exploit this mechanism by stabilizing the transient DNA–enzyme cleavage complex, preventing strand religation, and causing lethal double-strand breaks. These antibiotics are selectively...
01:25Clinical Significance of Antibiotic Resistance
Methicillin-resistant Staphylococcus aureus (MRSA) presents a critical public health threat, arising from its capacity to resist β-lactam antibiotics due to acquisition of the mecA gene within the staphylococcal cassette chromosome mec (SCCmec). This gene encodes penicillin-binding protein 2a (PBP2a), which impairs binding efficacy of methicillin and other β-lactams. MRSA has evolved into distinct clonal lineages impacting humans and animals alike, reinforcing its significance within the One...